RUO

    For laboratory research use only. Not for human or veterinary consumption. Not a drug, food, or dietary supplement. Not for diagnostic or therapeutic use.

    Repair & recovery

    KPV

    2 min readCAS 67727-97-3Updated 2026-11-05

    Also known as: Lys-Pro-Val · alpha-MSH 11-13

    Identity and specification

    CAS number
    67727-97-3
    Molecular formula
    C16H30N4O4
    Molar mass
    342.43 g/mol

    Batch certificates on file

    Figures below are copied from independent certificates prepared by ILS Laboratories, San Diego, CA. A figure describes one tested lot and nothing beyond it; the PDF holds the complete report and chromatogram.

    • Lot KP10-06 · KPV 10 mgView certificate (PDF)

      Purity specification
      ≥ 99.0% (HPLC)
      Lot result
      99.66% — Lot KP10-06, assayed 21 Jul 2026Average of all vials sampled in this lot: 99.30%
      Laboratory
      ILS Laboratories, San Diego, CA
      Method
      HPLC, identity by retention-time match to reference standard
      Certificate
      COA-2026-957001
      Labelled content
      10 mg
      Net peptide content
      10.26 mg
      Identity (HPLC-RTM)
      KPV — confirmed
      Heavy metals (ICP-MS)
      As, Cd, Cr, Hg, Pb — not detected
      Sterility (PCR)
      No growth
      Endotoxin (USP <85>)
      0.587 EU/mL
      Fentanyl screen
      Not detected
    • Lot KLW07 · KLOW blend 80 mgView certificate (PDF)

      Purity specification
      ≥ 99.0% (HPLC)
      Lot result
      99.87% — Lot KLW07, assayed 18 Aug 2026Average of all vials sampled in this lot: 99.87%
      Laboratory
      ILS Laboratories, San Diego, CA
      Method
      HPLC, identity by retention-time match to reference standard
      Certificate
      COA-2026-956995
      Labelled content
      80 mg
      Identity (HPLC-RTM)
      GHK-Cu + TB-500 + BPC-157 + KPV — confirmed
      Heavy metals (ICP-MS)
      As, Cd, Cr, Hg, Pb — not detected
      Sterility (PCR)
      No growth
      Endotoxin (USP <85>)
      0.098 EU/mL
      Fentanyl screen
      Not detected

    Published study designs

    Study parameters below are reported as published. They describe what each study did, not guidance of any kind.

    No study designs indexed yet.

    Identification and structure

    KPV is a tripeptide of lysine, proline and valine corresponding to the C-terminal 11-13 sequence of alpha-melanocyte-stimulating hormone. It is supplied as a lyophilised powder. Because the sequence is short, identity confirmation by mass spectrometry is straightforward and purity by reversed-phase HPLC is well resolved; short peptides also carry a higher relative risk of residual synthesis by-products, which is why the certificate of analysis and its stated method matter more, not less, for material of this class. Analytical values on this record are transcribed from supplier documentation.

    Discovery and characterisation history

    The fragment emerged from structure-activity work on alpha-MSH in the 1980s and 1990s, which sought the minimal sequence retaining the anti-inflammatory behaviour observed for the parent hormone in experimental systems. KPV was identified as a fragment that retained measurable activity in several assays while lacking the pigmentary activity associated with the full hormone. Research interest has remained largely in mucosal and dermal inflammation models.

    Mechanisms examined in published work

    Reported mechanisms centre on modulation of NF-kB signalling in cultured epithelial and immune cells, reductions in pro-inflammatory cytokine output in stimulated cell systems, and transport into cells via the peptide transporters PepT1 and PepT2 in intestinal and colonic models. Animal work has used chemically induced colitis models to examine mucosal inflammation endpoints. Some studies report antimicrobial behaviour in culture against fungal and bacterial species. Each of these is an assay-level observation in a defined system.

    Where the evidence is strong

    PepT1-mediated uptake in intestinal epithelial models is reasonably well supported and has been examined by more than one group. Reduction of NF-kB-driven cytokine readouts in stimulated epithelial culture is a consistent in vitro finding. The absence of pigmentary activity relative to the parent hormone is well established. As a three-residue peptide it is analytically simple and inexpensive to verify, which makes documentation failures harder to excuse.

    Where the evidence is thin or absent

    There are no completed randomised controlled human trials. The entire in vivo record is rodent, dominated by chemically induced colitis models that reproduce some but not all features of human inflammatory disease. Group sizes are small, and several of the most-cited findings rest on single studies from the same research programme without independent replication. Pharmacokinetic characterisation is minimal; the plasma half-life of an unmodified tripeptide is expected to be very short, and few papers address this directly. Antimicrobial reports are in vitro and use concentrations whose relevance to any intact system has not been established. The literature base here is genuinely thin, and a shorter honest record is the correct representation of it.

    Handling, stability and storage

    Store the lyophilised solid as stated on this record, protected from light and moisture, and allow the sealed vial to reach ambient temperature before opening. Short peptides are hygroscopic and degrade fastest under humidity and repeated temperature cycling. This section concerns laboratory handling of the material as supplied and provides no preparation or administration procedure.

    Referenced literature

    Indexed citations with verified PMIDs are listed below. Analytical methods behind the specification are described in testing methodology, documentation requirements in sourcing standards, and related records in the compound index.

    Handling and storage

    Handling conditions pending supplier documentation.

    Published research

    Evidence snapshot

    No records indexed — no distribution to plot.

    No literature is indexed for this compound on this site yet. Absence here is not evidence about the compound; it means nothing has been reviewed and published to this record.

    This compound is supplied with per-lot certificates of analysis.

    View supplier listing: KPV

    How to read this

    These entries index what has been published, not what has been established. Findings in cell culture or animal models do not transfer to human outcomes, and a citation appearing here is not a claim that the compound does anything in a person. None of these materials are approved for human or veterinary use. Summaries describe what each publication reported; read the source before relying on any of it.

    Browse the full research index

    Common questions

    What is the recorded identity of KPV?

    The reference record lists CAS number 67727-97-3, molecular formula C16H30N4O4, molar mass 342.43 g/mol. Identity is confirmed per batch by HPLC retention-time match and mass spectrometry on the certificate of analysis.

    Is KPV intended for human or veterinary use?

    No. KPV as catalogued here is a laboratory research material only. It is not a drug, food, or dietary supplement, and it is not for diagnostic or therapeutic use.

    Related compounds

    This material is catalogued by our supply partner as a research-use-only item. Batch documentation is issued with each shipment.

    Peptide calculator · Testing methodology · Sourcing standards · Compound index

    Research use only

    For laboratory research use only. Not for human or veterinary consumption. Not a drug, food, or dietary supplement. Not for diagnostic or therapeutic use. All materials referenced on this site are supplied to qualified laboratories and research institutions for in-vitro and analytical work.